GLPwatch
Papers (10378)
Page 104 of 173, ranked by citation count.
- Current and emerging pharmacotherapies for obesity in Australia.
- South Asian consensus guideline: Use of GLP-1 receptor agonists during Ramadan: Update 2016 Revised Guidelines on the use of GLP-1A in Ramadan.
- Reduction of prevalence of patients meeting the criteria for metabolic syndrome with tirzepatide: a post hoc analysis from the SURPASS Clinical Trial Program.
- Evaluating bowel obstruction and ileus events in patients on GLP-1 receptor agonists: a systematic review and meta-analysis.
- Evaluating the Efficacy and Pharmacoeconomics of Semaglutide and Tirzepatide in the Setting of Obesity.
- Risk of suicidal ideation and suicidality among adults prescribed semaglutide for weight management: A population-based cohort study.
- Risk of Sight-Threatening Diabetic Retinopathy with Glucagon-Like Peptide-1 Receptor Agonist Use in Routine Clinical Practice: Comparative Effectiveness of Semaglutide, Dulaglutide, Liraglutide, and Exenatide.
- Expectations and Outcomes From Glucagon-Like Peptide-1 Receptor Agonists As Adjunct Treatment for Type 1 Diabetes - Case Presentations.
- Tirzepatide to treat obesity: phase III results.
- Treatment Outcomes and Tolerability Following Initiation of GLP-1 Receptor Agonists Among Type 2 Diabetes Patients in Primary Care Practices in Germany.
- Role of incretin-based therapies and sodium-glucose co-transporter-2 inhibitors as adjuncts to insulin therapy in Type 2 diabetes, with special reference to IDegLira.
- Prepregnancy GLP-1RA use improves maternal lipid metabolism via liver-secreted FGF21 during pregnancy in HFD-fed dams.
- Pharmacotherapy for obstructive sleep apnea: a critical review of randomized placebo-controlled trials.
- Effect of once-weekly subcutaneous semaglutide on abdominal visceral fat area in Japanese adults with overweight and obesity: A post hoc analysis of the STEP 6 trial.
- Tirzepatide decreases systolic and diastolic blood pressure.
- An exploratory analysis of glucagon-like peptide-1 (GLP-1) agonists and biosimilars: A literature review.
- Quality of information and social norms in Spanish-speaking TikTok videos as levers of commercial practices: The case of semaglutide.
- Characterization of glucagon-like peptide-1 (GLP-1) agonist exposures reported to a single United States poison center.
- Improvement of Recalcitrant Folliculitis Decalvans With Tirzepatide: A Case Report.
- Efficacy and Safety of GLP- 1 Receptor Agonists in the Management of Weight Recurrence or Suboptimal Clinical Response after Undergoing Metabolic Bariatric Surgeries: A Meta-Analysis.
- The Effectiveness and Value of Oral Semaglutide for Type 2 Diabetes Mellitus.
- Tirzepatide for adults living with obesity.
- Activation of glucagon-like peptide-1 receptors and skilled reach foraging.
- Glucagon-like peptide-1 analog liraglutide reduces fat deposition in chicken adipocytes.
- Discontinuing semaglutide after weight loss: strategy for weight maintenance and a possible new side effect.
- Association between glucagon-like peptide-1 agonists and risk of diabetic retinopathy: a disproportionality analysis using FDA adverse event reporting system data.
- The Roles of Incretin Hormones GIP and GLP-1 in Metabolic and Cardiovascular Health: A Comprehensive Review.
- Using Second-Generation Anti-Obesity Medications.
- Psychiatric adverse events linked to glucagon-like peptide 1 analogues: a disproportionality analysis in American, Canadian and Australian adverse event databases.
- Efficacy and Safety of Glucagon-Like Peptide-1 Agonists for Psychiatric Symptoms: A Systematic Review.
- Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Obesity Management in Adults With and Without Type 2 Diabetes: A Systematic Review.
- GLP-1 receptor agonists: emerging therapeutic potential in psoriasis management - current evidence and future outlook.
- Semaglutide normalizes increased cardiomyocyte calcium transients in a rat model of high fat diet-induced obesity.
- Real-world glycated haemoglobin changes among type 2 diabetes mellitus patients treated with a maintenance dose of 7 mg or 14 mg of oral semaglutide.
- Network meta-analysis of liraglutide versus dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes in Japanese patients.
- Safety, Tolerability and Pharmacokinetics of Single Dose Polyethylene Glycolated Exenatide Injection (PB-119) in Healthy Volunteers.
- Beyond Diabetes: Semaglutide's Role in Modulating Mood Disorders through Neuroinflammation Pathways.
- In overweight or obesity without diabetes, weekly semaglutide vs. daily liraglutide increased weight loss at 68 wk.
- Cost-effectiveness of empagliflozin versus weekly semaglutide as add-on therapy for Type 2 diabetes.
- Efficacy, safety, and patient satisfaction with oral semaglutide: first single-centre clinical experience.
- Effects of semaglutide, empagliflozin and their combination on renal diffusion-weighted MRI and total kidney volume in patients with type 2 diabetes: a post hoc analysis from a 32 week randomised trial.
- Gut microbiota mediates semaglutide attenuation of diabetes-associated cognitive decline.
- A multiplicity of targets: evaluating composite endpoint studies of the GLP-1 receptor agonists in type 2 diabetes.
- Semaglutide (Wegovy) for the Treatment of Obesity.
- Plastic surgery amid a semaglutide epidemic: Direction for future studies and service implications.
- Coverage and Prior Authorization Policies for Semaglutide and Tirzepatide in Medicare Part D Plans.
- Semaglutide in NASH-related cirrhosis: too late to the party?
- Meta-Analysis Assessing the Cardiovascular Safety of Semaglutide for the Treatment of Overweight or Obesity.
- As Few as Three Months of Preoperative Semaglutide Exposure Prior to Total Knee Arthroplasty Is Associated With Reduced Postoperative Adverse Events in Patients Who Have Type II Diabetes.
- Effects of exenatide and liraglutide on 24-hour glucose fluctuations in type 2 diabetes.
- Semaglutide or Placebo for Nonalcoholic Steatohepatitis. Reply.
- Prolonged activity of exenatide: Detailed comparison of Site-specific linear polyglycerol- and poly(ethylene glycol)-conjugates.
- GLP-1R agonist therapy and vaccine response: Neglected implications.
- Resolution of symptoms of binge eating disorder associated with semaglutide treatment for obesity and type 1 diabetes.
- Survodutide in MASH: bridging the gap between hepatic and systemic metabolic dysfunction.
- MR Assessed Changes of Renal Sinus Fat in Response to Glucose Regulation in West European and South Asian Patients With Type 2 Diabetes.
- Oral Semaglutide (Rybelsus) for the Treatment of Type 2 Diabetes Mellitus.
- The SELECT trial of semaglutide in patients with overweight or obesity without diabetes: establishing a new pathway to secondary prevention of cardiovascular disease.
- REMODELing mechanistic trials for kidney disease: a multimodal, tissue-centered approach to understand the renal mechanism of action of semaglutide.
- Semaglutide single-dose pen-injector: Post hoc analysis of summative usability testing for weight management.